Pharmacogenomic Reporting

Clinically Actionable Intelligence

Translational Software® experts carefully curate pharmacogenomic (PGx) information such that interpretation can be delivered on-demand for medications used in cardiology, psychiatry, neurology, pain management, oncology, and more.

Our solutions transform pharmacogenetic test results into concise, actionable reports for physicians. Reports incorporate the latest guidance from scientific groups (e.g., the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)), governments (e.g., the Federal Drug Administration (FDA) and the European Medicines Agency (EMA)), and leading-edge science.

Pharmacogenomic testing for genes such as CYP2D6, CYP2C19 and CYP2C9

Lessons Learned: Guidelines for Effective Reporting

  • Few doctors are familiar with both the genetics and pharmacology behind drug response, so a pharmacogenetic test is not useful unless the test report explains the implications for care.
  • Alert fatigue is a real problem in clinical practice, so it is important to raise alerts only when appropriate; the test result may have no consequences if the patient is not receiving or is not be considered for a drug that is affected.
  • Doctors are under constant pressure to see more patients in the same amount of time, so tailoring reports to specific medications and specialties increases their efficiency and facilitates adoption.

Connect with us     to implement PGx reporting in your lab or for more information.

Pharmacogenomic tools help physicians choose safer and more effective treatments

How Genotypes Affect Drug Response

Clinicians recognize that patients respond to medications in different ways. They are accustomed to trying multiple drugs to find one that works, and wondering whether lack of efficacy is a mask for noncompliance or even drug abuse. For many common prescriptions, a simple genetic test can provide insight into the likely efficacy or toxicity of a drug, allowing a physician to choose safer and more effective treatments. Avoiding the need to re-do a stent, preventing an adverse reaction, or reducing an elderly patient’s mental fog can all significantly reduce health care costs – not to mention quality of life for the patient. Approximately 18% of prescriptions in the U.S. are for drugs that have clinically actionable guidance for particular genotypes (Nature, 2015).

Supported Drugs and Genes | Sample Reports | Clinical Utility of Preemptive Testing | Molecular Laboratory Implementation

Drug-Drug Interactions

Translational®’s Pharmacogenomic reports are offered with a Drug-Drug interaction analysis. This allows a clinician to decide on alternative medications based on multiple factors. This feature is also available in a dynamic tool, Medsreview through the Provider Portal or as an embedded app via the API

Drug-Drug Interaction (DDI) content is licensed from First Databank®. Read more about our partnership with [FDB]

To add Drug-Drug Interaction analysis to your pharmacogenomics reports.

Contact Us
Drug-Drug Interactions and Pharmacogenomic Testing

Pediatric Pharmacogenomic Reports

In collaboration with Inova® Genomics Laboratory (IGL), Translational Software® has developed new content for laboratories and providers serving pediatric populations. The report provides dosing information specific to pharmacogenetics in developing children that will help bridge the gap between adult pharmacogenetic clinical implementation and pediatric care. This includes educational information on the maturation trajectories of genes tested and the indications for each drug by age group.

To add pediatric guidance to your pharmacogenomic reports.

Start here

Examples

Cascading effects

When a breastfeeding mother has a rapid metabolizer genotype, she can unintentionally pass on a deadly dose to her infant when given a drug like codeine, which is metabolized into morphine.  Understanding a mother’s phamacogenomic profile enables a physician to protect both mother and child. See: Lancet 2006,368:704

q

Predictive power

The HIV therapy Abacavir can produce life-threatening hypersensitivity in 5 to 8% of patients. The allele HLA-B*5701, present in only 1-5% of the population, is strongly predictive of this deadly response. When testing for this genotype occurs, alternative therapies can be chosen. See: Medscape 2015, NEJM 2008

Right drug, right patient

Plavix (clopidogrel) is standard of care for preventing deadly clotting, heart attack or stroke after coronary stent surgery. However, 2-14% of the population does not metabolize this medication adequately, leaving them vulnerable even when alternative drugs are available. See:  FDA Black Box Warning, 2010